Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and intoxicating because that oh-so-familiar routine of meetings, deadlines, incessant messages, and the like has, of course, returned. To cope, yes, we are firing up the coffee kettle in order to brew cups of stimulation. Our choice today is hot buttered rum. Feel free to join us. Meanwhile, here are some tidbits to help you on your way. Hope all goes well today and you conquer the world …

Sanofi (SNY), Eli Lilly (LLY), and Novo Nordisk (NVO) must face claims they gouged diabetes patients through deceptive price lists for their life-saving drugs, Bloomberg News reports. A federal judge in New Jersey allowed a proposed class-action lawsuit filed by 67 people with diabetes against the companies to proceed on consumer-fraud allegations tied to skyrocketing insulin prices, but tossed racketeering claims. The patients contend the drug makers illegally raised insulin prices to provide rebates for pharmacy benefit managers that decide which medicines get on preferred insurance lists.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.